Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2

MIAMI, Dec 12, 2002 (BUSINESS WIRE) -- IVAX Corporation (IVX), (IVX.L) today announced that it has completed a phase I trial of TP-38 as a treatment of malignant brain tumors. The goal of the study was to evaluate the safety of TP-38 at dose levels up to and above those predicted to have an antitumor effect in pre-clinical models. No dose limiting toxicity was identified. At each dose level tested, clinical responses, either in the form of a partial response or prolonged disease stabilization were noted. One patient with a very heavily pre-treated and progressive glioblastoma involving both hemispheres of the brain had a dramatic near-complete response that continues 19 months after treatment at the lowest dose level studied.

Phillip Frost, M.D., Chairman and CEO of IVAX commented, "the responses seen in this phase I study in patients with refractory glioblastoma are very encouraging. Preparations for large multinational phase II studies in patients with less heavily pre-treated glioblastoma are in progress".

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.
Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement